




ELSEVIER

Contents lists available at ScienceDirect

## Molecular Genetics and Metabolism

journal homepage: [www.elsevier.com/locate/ygmme](http://www.elsevier.com/locate/ygmme)

## Corrigendum

## Corrigendum to “The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII” [*Mol Genet Metab* 2020 Mar;129(3):219–227]

Raymond Y. Wang<sup>a,i,\*</sup>, José Francisco da Silva Franco<sup>b,j</sup>, Jaime López-Valdez<sup>c</sup>, Esmeralda Martins<sup>d</sup>, Vernon Reid Sutton<sup>e</sup>, Chester B. Whitley<sup>f</sup>, Lin Zhang<sup>g</sup>, Tricia Cimms<sup>g</sup>, Deborah Marsden<sup>g</sup>, Agnieszka Jurecka<sup>g</sup>, Paul Harmatz<sup>h</sup>

<sup>a</sup> Division of Metabolic Disorders, Children's Hospital of Orange County, 1201 W. La Veta Ave, Orange, CA 92868, United States

<sup>b</sup> Hospital Sabara, Av. Angélica, 1987 Consolação, São Paulo, SP 01227-200, Brazil

<sup>c</sup> Centenario Hospital Miguel Hidalgo, Av. Gomez Morin S/N, La estación- La Alameda, Aguascalientes Ags 20259, Mexico

<sup>d</sup> Centro Hospitalar Do Porto, Hospital de Santo António, Porto, Largo do Prof. Abel Salazar, 4099-001 Porto, Portugal

<sup>e</sup> Department of Molecular & Human Genetics Baylor College of Medicine, Texas Children's Hospital, Mail Stop BCM225, Houston, TX 77030, United States

<sup>f</sup> Department of Pediatrics, and Experimental and Clinical Pharmacology, University of Minnesota, East Building, 2450 Riverside Ave, Minneapolis, MN 55454, United States

<sup>g</sup> Ultragenyx Pharmaceutical Inc., 60 Leveroni Ct, Novato, CA 94949, United States

<sup>h</sup> UCSF Benioff Children's Hospital Oakland, 744 52nd St, Oakland, CA 94609, United States

<sup>i</sup> Department of Pediatrics, University of California-Irvine, Orange, CA 92868, United States

<sup>j</sup> Centro de Biotecnologia, Instituto de Pesquisas de Energéticas e Nucleares IPEN/USP, Av 11 de junho 364, Casa 3, Vila Clementino, São Paulo 04041-001, Brazil



We would like to correct the [clinicaltrials.gov](https://clinicaltrials.gov) study registration number mentioned in the manuscript in several areas:

In the abstract, the NCT number mentioned and linked (NCT02377921) is incorrect. The sentence that reads “... completed a Phase 3, randomized, placebo-controlled, blind-start, single crossover study (UX003-CL301; NCT02377921) ...” should instead read, “... completed a Phase 3, randomized, placebo-controlled, blind-start,

single crossover study (UX003-CL301; NCT02230566) ...

The link to the corrected NCT number should point to: <https://clinicaltrials.gov/ct2/show/NCT02230566>

The authors would like to apologize for any inconvenience caused.

DOI of original article: doi: <https://doi.org/10.1016/j.ygmme.2020.01.003>

DOI of original article: <https://doi.org/10.1016/j.ygmme.2020.01.003>

\* Corresponding author at: Division of Metabolic Disorders, Children's Hospital of Orange County, 1201 W. La Veta Ave, Orange, CA 92868, United States.

E-mail addresses: [RaWang@choc.org](mailto:RaWang@choc.org) (R.Y. Wang), [vrsutton@texaschildrens.org](mailto:vrsutton@texaschildrens.org) (V.R. Sutton), [whitley@umn.edu](mailto:whitley@umn.edu) (C.B. Whitley),

[LZhang@ultragenyx.com](mailto:LZhang@ultragenyx.com) (L. Zhang), [TCimms@ultragenyx.com](mailto:TCimms@ultragenyx.com) (T. Cimms), [DMarsden@ultragenyx.com](mailto:DMarsden@ultragenyx.com) (D. Marsden), [AJurecka@ultragenyx.com](mailto:AJurecka@ultragenyx.com) (A. Jurecka), [Paul.Harmatz@UCSF.edu](mailto:Paul.Harmatz@UCSF.edu) (P. Harmatz).

<https://doi.org/10.1016/j.ygmme.2020.08.001>

Available online 23 August 2020

1096-7192/ © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.